On October 20, 2023 Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech") reported that it has received regulatory approval from the National Medical Products Administration (NMPA) to commence clinical trials for its proprietary novel ADC drug candidate SG2918 for injection, for the treatment of advanced malignant tumors (Press release, Sumgen Biotech, OCT 20, 2023, View Source;a=nav&id=355 [SID1234656271]). SG2918 is the first ADC candidate from Sumgen Biotech’s pipeline to be approved for clinical use, and it is first-in-class ADC approved for clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!